MEK阻害剤の世界市場:メキニスト、コテリック、メクトビ

LINEで送る

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• MEKINIST – Market size and forecast 2018-2023
• COTELLIC – Market size and forecast 2018-2023
• MEKTOVI – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 11: MARKET TRENDS
• Special drug designations
• Expanded application
• Use of protein biomarkers in diagnosis of NSCLC
PART 12: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 13: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• AstraZeneca Plc
• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Ono Pharmaceutical Co. Ltd.
• Pfizer Inc.
PART 14: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO


Exhibit 01: Product overview
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: MEKINIST – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: MEKINIST – Year-over-year growth 2019-2023 (%)
Exhibit 22: COTELLIC – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: COTELLIC – Year-over-year growth 2019-2023 (%)
Exhibit 24: MEKTOVI – Market size and forecast 2018-2023 ($ millions)
Exhibit 25: MEKTOVI – Year-over-year growth 2019-2023 (%)
Exhibit 26: Market opportunity by product
Exhibit 27: Customer landscape
Exhibit 28: Market share by geography 2018-2023 (%)
Exhibit 29: Geographic comparison
Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: North America – Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in North America
Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Country-wise age-standardized rate of melanomas in Europe 2018
Exhibit 35: Country-wise prevalence rate of NSCLC in Europe 2008
Exhibit 36: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 37: Top 3 countries in Europe
Exhibit 38: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 39: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 40: Top 3 countries in Asia
Exhibit 41: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 42: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 43: Top 3 countries in ROW
Exhibit 44: Key leading countries
Exhibit 45: Market opportunity
Exhibit 46: Alternative therapies based on MEK inhibitors for various oncology indications
Exhibit 47: Side effects of MEK and BRAF inhibitors
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Drug designations
Exhibit 50: Vendor landscape
Exhibit 51: Landscape disruption
Exhibit 52: Vendors covered
Exhibit 53: Vendor classification
Exhibit 54: Market positioning of vendors
Exhibit 55: AstraZeneca Plc – Vendor overview
Exhibit 56: AstraZeneca Plc – Business segments
Exhibit 57: AstraZeneca Plc – Organizational developments
Exhibit 58: AstraZeneca Plc – Geographic focus
Exhibit 59: AstraZeneca Plc – Key offerings
Exhibit 60: AstraZeneca Plc – Key customers
Exhibit 61: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 62: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 64: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 65: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 66: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 68: Novartis AG – Vendor overview
Exhibit 69: Novartis AG – Business segments
Exhibit 70: Novartis AG – Organizational developments
Exhibit 71: Novartis AG – Geographic focus
Exhibit 72: Novartis AG – Segment focus
Exhibit 73: Novartis AG – Key offerings
Exhibit 74: Novartis AG – Key customers
Exhibit 75: Ono Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 76: Ono Pharmaceutical Co. Ltd. – Business segments
Exhibit 77: Ono Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 78: Ono Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 79: Ono Pharmaceutical Co. Ltd. – Key offerings
Exhibit 80: Ono Pharmaceutical Co. Ltd. – Key customers
Exhibit 81: Pfizer Inc. – Vendor overview
Exhibit 82: Pfizer Inc. – Business segments
Exhibit 83: Pfizer Inc. – Organizational developments
Exhibit 84: Pfizer Inc. – Geographic focus
Exhibit 85: Pfizer Inc. – Segment focus
Exhibit 86: Pfizer Inc. – Key offerings
Exhibit 87: Pfizer Inc. – Key customers
Exhibit 88: Validation techniques employed for market sizing
Exhibit 89: Definition of market positioning of vendors




※当サイトのレポート紹介カバレッジ
■産業:医療、IT、電子、自動車、産業機械、建設、消費財、食品、化学、材料、エネルギー、金融、サービスなど多様
■地域:世界市場、アジア市場、中国市場、欧州市場、北米市場、中南米市場、中東市場、アフリカ市場など全世界
■レポート種類:市場動向、規模、占有率、トレンド、将来展望、未来予測、業界分析、産業分析、企業分析、事業機会分析、戦略提言など多様